Southwest Research Institute (SwRI), headquartered in San Antonio, Texas, is one of the oldest and largest independent, nonprofit, applied research and development (R&D) organizations in the United States.
Funded by
SwRI and UTSA
Collaborating Institutions
UTSA
Southwest Research Institute (SwRI) is collaborating with The University of Texas at San Antonio (UTSA) to explore and develop a novel platform or chemical process for synthesizing antibiotic compounds with a $125,000 grant. The project, one of two winning proposals this cycle, is supported by the Connecting through Research Partnerships (Connect) program designed to foster collaboration between SwRI and UTSA.
Southwest Research Institute (SwRI), headquartered in San Antonio, Texas, is one of the oldest and largest independent, nonprofit, applied research and development (R&D) organizations in the United States.
Principal Investigator(s)
Dr. Mike Rubal
Funded by
SwRI (internal funding)
Scientists at Southwest Research Institute have developed a new screening method to identify drug formulations that can penetrate the blood-brain barrier (BBB), to facilitate treatment of brain diseases and conditions.
Southwest Research Institute (SwRI), headquartered in San Antonio, Texas, is one of the oldest and largest independent, nonprofit, applied research and development (R&D) organizations in the United States.
Principal Investigator(s)
Dr. Tristan Adamson
Dillon Cao
Funded by
SwRI (internal research)
Southwest Research Institute (SwRI) has developed a unique technology to screen new DNA-targeting therapeutics designed to treat cancer and other diseases. Combining SwRI’s 3D drug screening software tool and machine learning techniques, SwRI scientists successfully predicted the DNA binding affinity and cancer cell toxicity for a variety of relevant drug compounds under development.
Southwest Research Institute (SwRI), headquartered in San Antonio, Texas, is one of the oldest and largest independent, nonprofit, applied research and development (R&D) organizations in the United States.
Principal Investigator(s)
Dr. Shawn Blumberg
Funded by
Medical CBRN Defense Consortium
Southwest Research Institute has developed a unique technology (US20230242487A1) that enables the safe and efficient synthesis of organophosphorus nerve agent (OPNA) oxime antidotes. Using this technology, SwRI scientists can not only successfully synthesize currently known highly effective nerve agent countermeasures, but also effectively develop promising new drug candidates to treat nerve agent exposure.
